DOCSLIB.ORG

Fidelity® Select Portfolio® Biotechnology Portfolio

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fidelity® Select Portfolio® Biotechnology Portfolio Quarterly Holdings Report for Fidelity® Select Portfolio® Biotechnology Portfolio May 31, 2021 BIO-QTLY-0721 1.802156.117 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 97.4% Shares Value Shares Value Biotechnology – 89.4% CareDx, Inc. (a) 178,500 $ 14,351,400 Biotechnology – 89.4% Celldex Therapeutics, Inc. (a) 337,900 9,444,305 4D Molecular Therapeutics, Inc. 214,868 $ 5,706,894 Cellectis SA sponsored ADR (a) (b) 157,465 2,467,477 AbbVie, Inc. 9,829,284 1,112,674,949 Cerevel Therapeutics Holdings (a) 201,800 2,647,616 ACADIA Pharmaceuticals, Inc. (a) 199,594 4,458,930 ChemoCentryx, Inc. (a) 2,062,222 20,931,553 Acceleron Pharma, Inc. (a) 924,453 121,001,653 Chinook Therapeutics, Inc. (a) 840,646 13,870,659 ADC Therapeutics SA (a) (b) 755,238 16,350,903 Chinook Therapeutics, Inc. rights (a) (d) 115,821 5,791 Agios Pharmaceuticals, Inc. (a) 1,075,059 59,966,791 Codiak Biosciences, Inc. (b) 436,539 9,874,512 Akouos, Inc. (a) (b) 716,626 9,359,136 Coherus BioSciences, Inc. (a) 58,387 768,373 Albireo Pharma, Inc. (a) (b) 320,350 10,715,708 Connect Biopharma Holdings Ltd. ADR (a) 1,079,600 16,064,448 Aldeyra Therapeutics, Inc. (a) 1,201,911 15,047,926 Constellation Pharmaceuticals, Inc. (a) (b) 90,259 1,788,031 Alector, Inc. (a) (b) 998,482 17,772,980 ContraFect Corp. (a) (b) 456,309 1,843,488 Allakos, Inc. (a) 207,631 21,062,089 Cortexyme, Inc. (a) (b) 1,947 80,547 Allena Pharmaceuticals, Inc. (a) (c) 1,447,443 1,577,713 Crinetics Pharmaceuticals, Inc. (a) (e) 2,123,187 37,261,932 Allena Pharmaceuticals, Inc. (a) (b) 848,640 925,018 CRISPR Therapeutics AG (a) (b) 260,522 30,788,490 Allogene Therapeutics, Inc. (a) 650,470 16,717,079 Cullinan Oncology, Inc. 179,440 5,334,751 Allovir, Inc. (a) 111,300 2,608,872 Cyclerion Therapeutics, Inc. (a) 837,285 2,712,803 Alnylam Pharmaceuticals, Inc. (a) 1,432,939 203,463,009 Cyclerion Therapeutics, Inc. (a) (f) 94,809 307,181 ALX Oncology Holdings, Inc. (a) (b) 643,290 36,384,482 Cytokinetics, Inc. (a) 1,546,871 33,768,194 Amgen, Inc. 401,451 95,521,251 CytomX Therapeutics, Inc. (a) 221,700 1,587,372 Amicus Therapeutics, Inc. (a) 1,229,001 11,380,549 CytomX Therapeutics, Inc. (a) (c) 287,485 2,058,393 Annexon, Inc. (a) 344,736 7,280,824 Day One Biopharmaceuticals, Inc. (a) 310,467 7,354,963 Apellis Pharmaceuticals, Inc. (a) 1,455,747 81,929,441 Decibel Therapeutics, Inc. 213,800 1,913,510 Applied Molecular Transport, Inc. (b) 25,628 1,228,606 Deciphera Pharmaceuticals, Inc. (a) 397,200 13,401,528 Applied Therapeutics, Inc. (a) 569,640 10,954,177 Denali Therapeutics, Inc. (a) (b) 697,951 44,382,704 Aravive, Inc. (a) (b) 456,443 2,341,553 Design Therapeutics, Inc. (a) 1,000,000 26,200,000 Arcturus Therapeutics Holdings, Inc. (a) (b) 730,290 21,339,074 Dicerna Pharmaceuticals, Inc. (a) 618,712 20,170,011 Arcus Biosciences, Inc. (a) 3,091,165 76,722,715 Edgewise Therapeutics, Inc. (a) 713,600 20,601,632 Arcutis Biotherapeutics, Inc. (a) 879,674 23,179,410 Editas Medicine, Inc. (a) (b) 9,789 332,337 Ardelyx, Inc. (a) 97,094 694,222 Eledon Pharmaceuticals, Inc. (a) (e) 1,004,111 9,559,137 Arena Pharmaceuticals, Inc. (a) 281,573 17,206,926 Emergent BioSolutions, Inc. (a) 18,101 1,097,826 Argenx SE ADR (a) 452,386 126,211,170 Epizyme, Inc. (a) (b) 1,799,135 14,806,881 Arrowhead Pharmaceuticals, Inc. (a) 1,052,226 76,391,608 Equillium, Inc. (a) 209,800 1,376,288 Ascendis Pharma A/S sponsored ADR (a) 659,409 88,611,381 Essa Pharma, Inc. (a) 797,203 25,207,559 Atara Biotherapeutics, Inc. (a) 587,995 7,973,212 Evelo Biosciences, Inc. (a) (b) 834,199 11,194,951 aTyr Pharma, Inc. (a) (b) 481,990 2,188,235 Exact Sciences Corp. (a) 526,212 58,162,212 Aurinia Pharmaceuticals, Inc. (a) (b) 1,263,586 18,347,269 Exelixis, Inc. (a) 3,524,744 79,482,977 Autolus Therapeutics Ltd. ADR (a) (b) 1,074,488 7,123,855 Fate Therapeutics, Inc. (a) 970,587 74,346,964 Avidity Biosciences, Inc. (b) 235,484 5,590,390 FibroGen, Inc. (a) 1,071,831 22,776,409 AVROBIO, Inc. (a) 120,951 1,087,349 Foghorn Therapeutics, Inc. 443,055 4,612,203 Axcella Health, Inc. (a) (b) 397,149 1,266,905 Foghorn Therapeutics, Inc. (c) 144,144 1,500,539 Bicycle Therapeutics PLC ADR (a) (b) 211,444 6,237,598 Forma Therapeutics Holdings, Inc. 804,809 22,590,989 BioAtla, Inc. 262,115 11,284,051 Fusion Pharmaceuticals, Inc. (a) 871,443 7,154,547 BioCryst Pharmaceuticals, Inc. (a) (b) 1,123,884 17,723,651 G1 Therapeutics, Inc. (a) (b) 813,600 17,671,392 Biogen, Inc. (a) 1,017,105 272,055,245 Galapagos Genomics NV sponsored ADR (a) (b) 564,459 42,977,908 Biohaven Pharmaceutical Holding Co. Ltd. (a) 1,128,162 98,150,094 Gamida Cell Ltd. (a) 795,067 5,159,985 BioMarin Pharmaceutical, Inc. (a) 8,344 644,991 Gemini Therapeutics, Inc. (f) 1,000,000 12,300,000 Biomea Fusion, Inc. (a) 335,863 5,813,789 Generation Bio Co. 137,100 4,697,046 BioNTech SE ADR (a) 164,628 33,584,112 Genmab A/S ADR (a) 21,490 872,924 BioXcel Therapeutics, Inc. (a) (b) 221,727 7,323,643 Geron Corp. (a) (b) 4,109,206 5,670,704 bluebird bio, Inc. (a) 12,384 385,390 Geron Corp. warrants 12/31/25 (a) 2,100,000 632,908 Blueprint Medicines Corp. (a) 1,304,915 119,203,985 Gilead Sciences, Inc. 448,782 29,668,978 Bolt Biotherapeutics, Inc. 423,000 7,406,730 Global Blood Therapeutics, Inc. (a) 413,716 15,899,106 BridgeBio Pharma, Inc. (a) (b) 696,761 41,248,251 Gritstone Bio, Inc. (a) (b) 780,780 7,183,176 C4 Therapeutics, Inc. (b) 357,691 13,216,682 Halozyme Therapeutics, Inc. (a) 906,308 37,530,214 Cabaletta Bio, Inc. (a) (b) 35,650 404,271 Heron Therapeutics, Inc. (a) (b) 354,625 4,705,874 Homology Medicines, Inc. (a) 1,057,874 7,024,283 Quarterly Report 2 Common Stocks – continued Shares Value Shares Value Biotechnology – continued Nkarta, Inc. (a) (b) 60,200 $ 1,465,870 Biotechnology – continued Novavax, Inc. (a) 368,936 54,462,332 Hookipa Pharma, Inc. (a) (b) (e) 1,405,103 $ 23,451,169 NuCana PLC ADR (a) 369,200 1,129,752 Ideaya Biosciences, Inc. (a) 44,000 886,600 Nurix Therapeutics, Inc. (a) (b) 564,634 15,753,289 Idorsia Ltd. (a) 1,218,641 33,273,844 Olema Pharmaceuticals, Inc. (b) 61,997 1,733,436 IGM Biosciences, Inc. (a) 99,368 7,417,821 Opko Health, Inc. (a) (b) 1,434,911 5,481,360 Immunic, Inc. (a) 602,072 8,133,993 Oragenics, Inc. (a) 155,806 107,008 Immunocore Holdings PLC 400,875 15,614,081 ORIC Pharmaceuticals, Inc. (a) (b) 724,374 16,551,946 ImmunoGen, Inc. (a) 1,176,923 7,273,384 Passage Bio, Inc. (a) 643,962 8,532,497 Immunome, Inc. (b) 226,456 4,737,460 PMV Pharmaceuticals, Inc. (b) 172,300 5,927,120 Incyte Corp. (a) 760,067 63,678,413 Poseida Therapeutics, Inc. (a) 101,700 859,365 Inhibikase Therapeutics, Inc. (b) 100,000 537,000 Poseida Therapeutics, Inc. (c) 513,583 4,339,776 Inozyme Pharma, Inc. (a) (b) 609,380 9,969,457 Praxis Precision Medicines, Inc. 321,261 6,293,503 Insmed, Inc. (a) 742,920 18,275,832 Prelude Therapeutics, Inc. 10,079 350,346 Instil Bio, Inc. (a) 63,200 1,124,960 Prelude Therapeutics, Inc. (c) 550,977 19,151,961 Instil Bio, Inc. 1,431,274 22,929,009 Prometheus Biosciences, Inc. (a) (b) 412,800 9,614,112 Intellia Therapeutics, Inc. (a) 1,150,501 86,218,545 ProQR Therapeutics BV (a) (b) 555,016 3,463,300 Intercept Pharmaceuticals, Inc. (a) (b) 102,794 1,709,464 Protagonist Therapeutics, Inc. (a) 564,855 19,832,059 Invitae Corp. (a) (b) 657,417 18,920,461 Prothena Corp. PLC (a) 1,060,789 30,943,215 Ionis Pharmaceuticals, Inc. (a) (b) 1,722,677 64,169,718 PTC Therapeutics, Inc. (a) 2,268,744 89,093,577 Iovance Biotherapeutics, Inc. (a) 779,179 14,469,354 Radius Health, Inc. (a) 40,249 776,403 iTeos Therapeutics, Inc. (a) 303,681 6,237,608 Rain Therapeutics, Inc. (a) (b) 800,000 15,896,000 Jounce Therapeutics, Inc. (a) 790,934 6,208,832 Recursion Pharmaceuticals, Inc. (a) 220,300 5,807,108 Kalvista Pharmaceuticals, Inc. (a) (b) 218,620 5,902,740 Regeneron Pharmaceuticals, Inc. (a) 14,976 7,524,392 Karuna Therapeutics, Inc. (a) 229,311 25,641,556 REGENXBIO, Inc. (a) 15,108 532,859 Keros Therapeutics, Inc. (a) 310,786 16,956,484 Relay Therapeutics, Inc. (a) (b) 1,319,943 42,396,569 Kezar Life Sciences, Inc. (a) 814,232 4,657,407 Repare Therapeutics, Inc. 540,250 17,460,880 Kiniksa Pharmaceuticals Ltd. (a) (b) 305,540 4,164,510 Replimune Group, Inc. (a) 1,054,117 41,078,939 Kinnate Biopharma, Inc. 639,303 14,860,726 Revolution Medicines, Inc.
Load more

Recommended publications
  • Biotech Investing 2020
    BIOTECH INVESTING 2020 Bill Cara www.billcara.com [email protected] 647-868-6013 JULY 20, 2020 A. Report Overview This Greenfield Capital (billcara.com) report on the Biotechnology industry is written by a registered investment consultant & portfolio manager, not by a scientist. Our objective is to provide education and information to investors who lack the tools to trade successfully in an industry made vitally important to the world by the coronavirus pandemic of 2020. If we want to live through this pandemic -- and future ones -- where it is possible that hundreds of millions of us could perish because of the lack of diagnostics, vaccines, and therapeutics, then as investors we should be keenly interested in the Biotech industry. News reports state that in just six and a half months, COVID-19, initially called SARS- CoV-2, has killed more people than the number of Americans who die each year from opioid overdose (46,000), traffic accidents (36,500), and gun violence (40,000) combined. But, currently, there is no vaccine for COVID-19, and the treatment options for patients with severe or life-threatening symptoms are limited. As the world struggles to contain the deadly virus, there are, fortunately, over 140 coronavirus vaccines in development. News is breaking every day. At the same time, however, many individuals who are trading in Biotech stocks remain woefully uninformed and are speculating wildly. Some Biotech stocks that have appreciated 100% or more in a few months on hopefulness may have trouble sustaining gains beyond the news peak. Still, for investors who study this industry, there are opportunities right now to buy Biotech stocks that will grow in price well into the future.
    [Show full text]
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • Based on Our Discussion with Radford, Management Identified Our Peer Companies to Include the Following 19 Biotechnology and Pharmaceutical Companies for 2015
    Based on our discussion with Radford, management identified our peer companies to include the following 19 biotechnology and pharmaceutical companies for 2015: Ariad Pharmaceuticals Inc. Infinity Pharmaceuticals, Inc. Progenics Pharmaceuticals, Inc. Array BiopPharma, Inc. Lexicon Pharmaceuticals, Inc Repligen Corporation Celldex Therapeutics, Inc. MacroGenics, Inc. Spectrum Pharmaceuticals, Inc. CTI BioPharma Corp. Merrimack Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. DepoMed Inc. NewLink Genetics Corporation XOMA Corporation Halozyme Therpeutics, Inc. OncoMed Pharmaceuticals, Inc. Immunomedics Inc. Peregrine Pharmaceuticals, Inc These peer companies were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations in mid– to late–stages of product development or small commercial products in the U.S. based on the following criteria: number and stage of development programs; number of employees; market capitalization; and number of and revenue from commercial products. The market data included information as to base salaries, cash bonuses and stock option awards. Use of Compensation Consultants Our Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Our Compensation Committee engaged Radford to analyze historic compensation and establish recommendations for executive compensation for 2015 and methodologies for determining compensation on an on-going basis. Benchmarking in the Context of Our Other Executive Compensation Principles Our Compensation Committee and our Board of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer is believed to be especially suited to our company or important to our success, the Compensation Committee may establish or recommend compensation that deviates from industry averages or other specific benchmarks.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Preclinical Evidence for and Clinical Development of XERMELO in Cancer Ranuka Iyer, M.D
    April 10, 2018 Welcome and Introduction Kimberly Lee, D.O. Head of Investor Relations and Corporate Strategy Precision Science. Pioneering Medicine. Patient Driven. 0 ©Precision 2018 Lexicon Pharmaceuticals, Science. Inc. Pioneering Medicine. Patient Driven. Forward-looking Statements This presentation, including any oral presentation accompanying it, contains “forward- looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the level of market acceptance and commercial success of XERMELO®, the results of and expected timing of the completion of our ongoing and future clinical trials, the expected timing and outcome of discussions with regulatory authorities regarding such trials, the expected timing of initiation of our other planned clinical trials, the expected enrollment in our ongoing and future clinical trials, our other research and development efforts, the status of activities performed under our collaborative agreements and the anticipated trends in our business. These forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, including the sections entitled “Risk Factors,” as well as our current reports on Form 8-K, in each case filed with the Securities and Exchange Commission.
    [Show full text]
  • Active Labelers Run Date : Feb 19, 2018
    Active Labelers Run Date : Feb 19, 2018 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 01/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 01/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 01/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PFIZER, INC 01/01/1991 01/01/3000 00013 PFIZER, INC. 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 01/01/1991 01/01/3000 00023 ALLERGAN INC 01/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00025 PFIZER, INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 01/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 01/01/1991 01/01/3000 00046 AYERST LABORATORIES 01/01/1991 01/01/3000 00049 PFIZER, INC 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 01/01/1991 01/01/3000 00053 CSL BEHRING LLC 01/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 01/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 01/01/1991 01/01/3000 00062 ORTHO MCNEIL PHARMACEUTICALS 01/01/1991 01/01/3000 00064 HEALTHPOINT, LTD.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Preliminary Healthcare Agenda 01.03X
    29th Annual J.P. Morgan Healthcare Conference January 10 - 13, 2011 Westin St. Francis Hotel, San Francisco, CA Preliminary Conference Agenda SUNDAY, JANUARY 9 - Registration in Tower Salon A - 3 to 9 PM MONDAY, JANUARY 10 - Registration in Tower Salon A - 6:45 AM, Breakfast in Italian Foyer Grand Ballroom Colonial Room California West California East Elizabethan A/B Elizabethan C/D Alexandra's Breakout: Borgia Room Breakout: Georgian Room Breakout: Olympic Room Breakout: Yorkshire Room Breakout: Sussex Room Private Company Track Not-for-Profit Track 7:30 AM Opening Remarks: Doug Braunstein - Chief Financial Officer, JPMorgan Chase & Co., Grand Ballroom Astra Tech 8:00 AM Celgene Corporation Kinetic Concepts, Inc Alkermes, Inc. Biocon Limited Catalent (private company) 8:30 AM Express Scripts Inc. Agilent Technologies Inc. Beckman Coulter Inc. Bio-Rad Laboratories, Inc. Quality Systems Axcan Intermediate Holdings 9:00 AM Roche Holding AG Zimmer Holdings, Inc. Genoptix, Inc. ImmunoGen, Inc Health Net Inc. Merrimack Pharmaceuticals Inc. Vertex Pharmaceuticals Allscripts Healthcare Solutions, 9:30 AM Medicis Pharmaceutical Corp. Lonza Group Ltd Henry Schein Inc. Surgical Care Affiliates Incorporated Inc. 10:00 AM Medtronic, Inc. WellPoint, Inc. Onyx Pharmaceuticals Inc. Sigma-Aldrich Corporation Align Technology Inc.* Symphogen 10:30 AM Room Not Available Medco Health Solutions, Inc. Smith & Nephew plc* Medivation, Inc. Lexicon Pharmaceuticals, Inc. Zeltiq Aesthetics 11:00 AM Room Not Available Merck KGaA Perrigo Company Healthways Incorporated BioMimetic Therapeutics, Inc. Penumbra, Inc. 11:30 AM Room Not Available Dendreon Corporation Gen-Probe Inc. Select Medical Corporation ArthroCare Corporation PTC Therapeutics, Inc. 12:00 PM Luncheon & Keynote: Nancy-Ann DeParle - Counselor to the President and Director of the White House Office of Health Reform, Grand Ballroom Endo Pharmaceuticals Holdings 1:30 PM Room Not Available Amylin Pharmaceuticals Inc.
    [Show full text]